Table 1 Clinical characteristics and... | American Society of Hematology

Table 1

Clinical characteristics and their outcome association (EFS)

	Entire cohort				MLL-AFF1 patients
	Value*	HR (SE)†	5-y EFS (SE)‡	P§	Value*	HR (SE)†	5-y EFS (SE)‡	P§
Overall
Total	97 (100)		0.41 (.05)		48 (100)		0.36 (.07)
Age				.009				.002
≤ 90 days	24 (25)	2.13 (.62)	.19 (.09)		12 (25)	3.25 (1.30)	0 (NA)
> 90 days	73 (75)	1	.48 (.06)		36 (75)	1	.47 (.08)
Sex				.745				.099
Male	54 (56)	1.09 (.30)	.40 (.07)		26 (54)	1.82 (.68)	.28 (.09)
Female	43 (44)	1	.42 (.08)		22 (46)	1	.45 (.11)
WBC				.006				.228
≥ 50 × 10³/μL	83 (86)	5.70 (4.11)	.35 (.05)		43 (91)	3.20 (3.26)	.33 (.07)
< 50 × 10³/μL	13 (14)	1	.84 (.10)		4 (9)	1	.75 (.22)
*MLL* status				.008
Rearranged	80 (82)	3.23 (1.52)	.35 (.05)		48 (100)		.36 (.07)
Germline	17 (18)	1	.69 (.12)		0 (0)

	Entire cohort				MLL-AFF1 patients
	Value*	HR (SE)†	5-y EFS (SE)‡	P§	Value*	HR (SE)†	5-y EFS (SE)‡	P§
Overall
Total	97 (100)		0.41 (.05)		48 (100)		0.36 (.07)
Age				.009				.002
≤ 90 days	24 (25)	2.13 (.62)	.19 (.09)		12 (25)	3.25 (1.30)	0 (NA)
> 90 days	73 (75)	1	.48 (.06)		36 (75)	1	.47 (.08)
Sex				.745				.099
Male	54 (56)	1.09 (.30)	.40 (.07)		26 (54)	1.82 (.68)	.28 (.09)
Female	43 (44)	1	.42 (.08)		22 (46)	1	.45 (.11)
WBC				.006				.228
≥ 50 × 10³/μL	83 (86)	5.70 (4.11)	.35 (.05)		43 (91)	3.20 (3.26)	.33 (.07)
< 50 × 10³/μL	13 (14)	1	.84 (.10)		4 (9)	1	.75 (.22)
*MLL* status				.008
Rearranged	80 (82)	3.23 (1.52)	.35 (.05)		48 (100)		.36 (.07)
Germline	17 (18)	1	.69 (.12)		0 (0)

NA indicates not applicable.

Values are number and percentage of infants in parentheses.

HR is relative to the reference category (with HR = 1). SE indicates the standard error for each HR.

Five-year EFS survival probability and SE.

P value of log-rank test.